Current problems in cardiology · 2025
Factors associated with heart failure severity and mortality in Butembo between 2021 and 2023.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Paluku Mwalitsa Jean-Paul, Mbo Mukongole Jean-Paulin, Tsongo Kibendelwa Zacharie, Kambale Munyambalu Dalton, Sahika Serge Muyisa, Katsuva Mbahweka François, Nzanzu Arma Fiston, Muhindo Muyisa Roland, Kambale Ngesera, Nzanzu Kalima Adélar, Kasereka Masumbuko Claude
Аннотация
BACKGROUND: Heart failure is a syndrome with high morbidity and mortality, influenced by various regional factors.
OBJECTIVE: This study aimed to enhance heart failure management by identifying factors that can improve the quality of life and survival of patients in eastern DR Congo.
METHODS: Conducted from January 1, 2022, to December 31, 2023, this descriptive analytical study included 156 heart failure patients (mean age 62 ± 15), comprising 80 males and 76 females. Each patient was followed for 12 months.
RESULTS: The frequency of heart failure was 17.5 % (156 out of 2732 patients) at the cardiology center. Severity correlated with the use of indigenous anti-poison products (p 0.000) and valvular heart disease (p 0.000). Mortality was notably influenced by indigenous anti-poison product use (41.2 % mortality; p 0.000), duration of diabetes (≤ 1 year 7.4 %; 2-5 years 11.1 %; > 5 years 33.3 %; p 0.014), dilated cardiomyopathy (18.9 % vs. 1.2 % for non-dilated; p 0.000), and valvular heart disease (17.5 % vs. 1.3 %; p 0.003). Mortality rates varied by heart failure phenotype (HFrEF 30.9 %, HFmEF 5.1 %, HFpEF 0.0 %; p 0.000) and severity (NYHA IV 55.6 % vs. NYHA I and II 0.0 %).
CONCLUSION: Indigenous anti-poison products and rheumatic valvular heart disease contribute to the worsening and premature death of heart failure patients. Addressing these factors may improve patient survival in this region.
OBJECTIVE: This study aimed to enhance heart failure management by identifying factors that can improve the quality of life and survival of patients in eastern DR Congo.
METHODS: Conducted from January 1, 2022, to December 31, 2023, this descriptive analytical study included 156 heart failure patients (mean age 62 ± 15), comprising 80 males and 76 females. Each patient was followed for 12 months.
RESULTS: The frequency of heart failure was 17.5 % (156 out of 2732 patients) at the cardiology center. Severity correlated with the use of indigenous anti-poison products (p 0.000) and valvular heart disease (p 0.000). Mortality was notably influenced by indigenous anti-poison product use (41.2 % mortality; p 0.000), duration of diabetes (≤ 1 year 7.4 %; 2-5 years 11.1 %; > 5 years 33.3 %; p 0.014), dilated cardiomyopathy (18.9 % vs. 1.2 % for non-dilated; p 0.000), and valvular heart disease (17.5 % vs. 1.3 %; p 0.003). Mortality rates varied by heart failure phenotype (HFrEF 30.9 %, HFmEF 5.1 %, HFpEF 0.0 %; p 0.000) and severity (NYHA IV 55.6 % vs. NYHA I and II 0.0 %).
CONCLUSION: Indigenous anti-poison products and rheumatic valvular heart disease contribute to the worsening and premature death of heart failure patients. Addressing these factors may improve patient survival in this region.